News
RDHL
0.3700
-1.36%
-0.0051
Weekly Report: what happened at RDHL last week (1102-1106)?
Weekly Report · 2d ago
RedHill Biopharma Reports RHB-204 MAP-Killing Confirmation
TipRanks · 11/02 12:25
RedHill Biopharma’s RHB-204 shows MAP-killing efficacy in Crohn’s Disease
TipRanks · 11/02 12:10
Redhill Biopharma Announced Confirmation Of RHB-204's Killing Capability On Mycobacterium Avium Subspecies Paratuberculosis And Its Comparability To RHB-104 MAP-Killing
Benzinga · 11/02 12:06
Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate
PR Newswire · 11/02 12:00
Weekly Report: what happened at RDHL last week (1026-1030)?
Weekly Report · 11/02 09:58
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 10/28 12:05
'Congo Ebola Cases Top 10,000 as Violence Hits Health Workers' - Bloomberg
Benzinga · 10/27 12:39
Weekly Report: what happened at RDHL last week (1019-1023)?
Weekly Report · 10/26 09:58
RedHill Biopharma Regains Global Rights to RHB-102 After Hyloris Deal Termination
TipRanks · 10/21 11:27
RedHill Biopharma Backs $2.9 Million NCI-Funded Opaganib–CAR T Trial in Ultra-High-Risk Myeloma
TipRanks · 10/19 12:27
RedHill Biopharma’s Partner University Of Oklahoma Receives $2.9M In Funding From National Cancer Institute To Study, In Clinical Trials, Whether RedHill's Opaganib, Given After CAR T-Cell Therapy, May Help Immune Cells Fight Cancer More Effectively
Benzinga · 10/19 12:10
Weekly Report: what happened at RDHL last week (1012-1016)?
Weekly Report · 10/19 09:58
RedHill Biopharma Expands U.S. ATM ADS Offering With New Prospectus Supplement
TipRanks · 10/13 20:35
Weekly Report: what happened at RDHL last week (1005-1009)?
Weekly Report · 10/12 10:02
RedHill Biopharma Wins Nasdaq Bid-Price Compliance Extension to April 2027
TipRanks · 10/07 12:27
Weekly Report: what happened at RDHL last week (0928-1002)?
Weekly Report · 10/05 10:02
RedHill Biopharma Reshapes GI Portfolio With Asset Sale and New Licensing Deals
TipRanks · 09/30 20:47
Redhill Biopharma H1 2026 EPS $0.00 And Revenue $0.00
Benzinga · 09/30 20:36
RedHill Biopharma Reshapes GI Portfolio With Rebyota, Clenpiq Deal and Talicia Sale
TipRanks · 09/30 20:27
More
Webull provides a variety of real-time RDHL stock news. You can receive the latest news about Redhill Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About RDHL
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204, for pulmonary nontuberculous mycobacteria (NTM) disease; opaganib (ABC294640), host-directed, SPHK2 inhibitor targeting multiple indications, RHB-107 (upamostat), an oral, host-directed serine protease inhibitor with potential for pandemic preparedness, is in late-stage development for treatment of non-hospitalized symptomatic COVID-19, and is targeting multiple other cancer and inflammatory gastrointestinal diseases; RHB-104 for Crohn's disease; and RHB-102 for chemotherapy and radiotherapy induced nausea and vomiting.